摘要
目的:探讨及评价奥沙利铂(L-OHP)联合卡培他滨(Capecitabine,希罗达)治疗晚期直肠癌的客观疗效及毒性反应。方法:回顾性分析23例经病理证实均为晚期直肠癌患者的临床资料。具体用法:奥沙利铂130mg/m2,静脉滴注2h,d1;卡培他滨1000mg/m2,口服,2次/d,d1~14。21d为1周期,化疗2个或2个周期以上评价疗效及其毒性反应。结果:23例患者均可评价疗效,CR4例,PR11例,SD5例,PD3例,有效率(RR)为65.21%(15/23);肿瘤中位进展时间为8.2个月。毒性反应主要为骨髓抑制、神经毒性及腹泻。结论:奥沙利铂联合卡培他滨治疗晚期直肠癌有相对较好疗效,毒副反应可以耐受,用药安全,值得临床进一步推广。
Objective:To evaluate the efficacy and toxicity of advanced rectal cancer treated with oxaliplatin combined capecitabine.Method:23 patients with locally advanced rectal cancer were retrospectively analyzed.Advanced rectal cancer basede chemotherapy received oxaliplatin(130 mg/m2 iv gtt)on day 1 and capecitabine(1000 mg/m2 po bid)on day 1 to 14,the regimen was repeated every 3 weeks and efficacy and toxicity were evaluated after 2 cycles.Result:In 23 evaluable patients,4 cases had completed response,11 cases had partial response,5 cases had stable disease and 3 cases with progressive disease.The response rate of the whole group was 65.21%.Median time to progression was 7.2 months.The main toxicities were myelosuppression,neutropenia and diarrhea.Conclusion:The regimen oxaliplatin combined capecitabine for advanced rectal cancer show more effectiveness and all adverse reactions are tolerable,which is worthy of further clinical research.
出处
《中国医学创新》
CAS
2012年第30期17-18,共2页
Medical Innovation of China
关键词
晚期直肠癌
奥沙利铂
卡培他滨
化学治疗
Advansed rectal cancer
Oxaliplatin
Capecitabine
Chemotherapy